EHA 2023 | An overview of the safety profile of FLT3 inhibitors in AML
Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, comments on the safety profile of currently available and investigational FLT3 inhibitors for acute myeloid leukemia (AML) including sorafenib, midostaurin, gilteritinib, quizartinib, and crenolanib. Dr Loschi highlights the importance of cardiac monitoring and of being aware of potential interactions with cytochrome P450 3A4 (CYP3A4). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honorarium : Novartis, Gilead, Pfizer, Sobi, BMS, Abbvie, Janssen, Astra zeneca, Alexion, GSK, Incyte, Morphosys, Telios, Kartos
